
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Tatva Chintan Pharma Chem Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.

Price Band
₹1,083
Per Share
Lot Size
13 Shares

Minimum Investment
₹14,079

Issue Size
₹500 Cr

Face Value
₹10
Per Share
IPO Type
Book Building

Retail Quota
35%

QIB Quota
50%

NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
80.53%
Issue Type
Book Building
ISIN
INE0GK401011
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of SDAs, PTCs, electrolyte salts for super capacitor batteries and PASCs. The Company is the largest and only commercial manufacturer of SDAs for zeolites in India and enjoys the second largest position globally. The Company is also one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe.
The global chemicals market is valued at around USD 4,738 billion and is expected to grow at 6.2% CAGR; reaching USD 6,400 billion by 2024. The Indian chemicals market is valued at USD 166 billion (~4% share in the global chemical industry) and it is expected to reach ~USD 280-300 Bn in the next 5 years, with an anticipated growth of ~12% CAGR. The specialty chemical industry forms ~47% of the domestic chemical market, which is expected to grow at a CAGR of around 11-12% over the same period
Tatva Chintan Pharma Chem Limited was incorporated as `Tatva Chintan Pharma Chem Private Limited' pursuant to a certificate of incorporation dated June 12, 1996 issued by the Registrar of Companies, Gujarat and Dadra & Nagar Haveli at Ahmedabad ("RoC"). Thereafter, pursuant to the conversion of the Company to a public limited company, the name of the Company was changed to `Tatva Chintan Pharma Chem Limited', and a fresh certificate of incorporation dated February 26, 2021 was issued to the Company by the RoC.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 4,616,804 equity shares of face value of Rs. 10 each ("equity shares") of Tatva Chintan Pharma Chem Limited ("the company" or the "issuer") for cash at a price of Rs. 1,083 per equity share (including a premium of Rs. 1,073 per equity share) ("offer price" aggregating to Rs. 500 Crores. The offer comprises of a fresh issue of 2,077,562 equity shares aggregating to Rs. 225 Crores ("fresh issue") and an offer for sale of 2,539,242 equity shares aggregating to Rs. 275 Crores, comprising 215,143 equity shares aggregating to Rs. 23.30 Crores by Ajaykumar Mansukhlal Patel, 751,616 equity shares aggregating to Rs. 81.40 Crores by Chintan Nitinkumar Shah, and 674,054 equity shares aggregating to Rs. 73 Crores by Shekhar Rasiklal Somani (collectively the "promoter selling shareholders") and 95,106 equity shares aggregating to Rs. 10.30 Crores by Darshana Nitinkumar Shah, 315,789 equity shares aggregating to Rs. 34.20 Crores by Priti Ajaykumar Patel, 315,789 equity shares aggregating to Rs. 34.20 Crores by Ajay Mansukhlal Patel Huf, 101,570 equity shares aggregating to Rs. 11 Crores by Kajal Shekhar Somani, 10,157 equity shares aggregating to Rs. 1.10 Crores by Shitalkumar Rasiklal Somani, and 60,018 equity shares aggregating to Rs. 6.50 Crores by Samirkumar Rasiklal Somani (collectively The "promoter group selling shareholders", and together with the promoter selling shareholders, the "selling shareholders") (the "offer for sale", and together with the fresh issue, the "offer"). The offer constitutes 20.83% of the post-offer paid-up equity share capital. Offer Price : Rs. 1083 per equity shares of face value of Rs. 10 Each. Anchor Investor offer price : Rs. 1083 per equity share. The offer price is 108.3 times the face value.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Merck, Bayer AG, Asian Paints Ltd, Ipox Chemicals KFT, Laurus Labs Ltd, Tosoh Asia Pte. Ltd, SRF Ltd, Navin Fluorine International Ltd, Oriental Aromatics Ltd, Atul Ltd, Otsuka Chemical (I) Pvt Ltd, Meghmani Organics Ltd, Divi's Laboratories Ltd, Hawks Chemical Company Ltd, Firmenich Aromatics Prod. (I) Pvt. Ltd, Jiangsu Guotai Super Power New Materials Co. Ltd, Jade Chem Co. Ltd
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.